Protara Therapeutics
TARA · Nasdaq · United States
Share price · TARA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TARA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+7.8%
Nothing announced by TARA that day or the session before.
- 9 Nov 2026+9.1%
- 6 Nov 2026+8.0%
- 20 Oct 2026+9.9%
Nothing announced by TARA that day or the session before.
- 15 Oct 2026-3.2%
- 14 Oct 2026-5.3%
Nothing announced by TARA that day or the session before.
- 1 Oct 2026-9.5%
Nothing announced by TARA that day or the session before.
- 30 Sep 2026-5.0%
Nothing announced by TARA that day or the session before.
- 24 Sep 2026-5.4%
Nothing announced by TARA that day or the session before.
- 1 Jul 2026+5.8%
Nothing announced by TARA that day or the session before.
Share of unusual movement by asset
For each asset, the share of TARA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Innate and adaptive immune activation (inactivated Streptococcus pyogenes)Bacterial immunotherapy | Bladder / Urothelial Cancer Non-Muscle Invasive Bladder Cancer |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2028 (1)
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $17M | $26M+ $102M short-term inv. | $22M-$18M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $17M | $18M+ $125M short-term inv. | $22M-$15M operating cash flow | report ↗ |
| 2026-Q1 | — | $14M | $15M+ $121M short-term inv. | $18M-$21M operating cash flow | report ↗ |
| 2025-Q3 | — | $9.6M | $13M+ $120M short-term inv. | $13M-$12M operating cash flow | report ↗ |
| 2025-Q2 | — | $11M | $32M+ $91M short-term inv. | $15M-$12M operating cash flow | report ↗ |
| 2025-Q1 | — | $9.2M | $92M+ $33M short-term inv. | $12M-$15M operating cash flow | report ↗ |
| 2024-Q3 | — | $8.1M | $53M+ $30M short-term inv. | $11M-$8.4M operating cash flow | report ↗ |
| 2024-Q2 | — | $6.4M | $90M | $9.5M-$7.7M operating cash flow | report ↗ |
| 2024-Q1 | — | $7.8M | $53M+ $3.0M short-term inv. | $11M-$10M operating cash flow | report ↗ |
| 2023-Q3 | — | $6.2M | $35M+ $40M short-term inv. | $9.9M-$6.6M operating cash flow | report ↗ |
| 2023-Q2 | — | $7.3M | $35M+ $46M short-term inv. | $11M-$9.4M operating cash flow | report ↗ |
| 2023-Q1 | — | $5.1M | $22M+ $66M short-term inv. | $9.1M-$13M operating cash flow | report ↗ |
| 2022-Q3 | — | $3.5M | $48M+ $49M short-term inv. | $7.7M-$5.3M operating cash flow | report ↗ |
| 2022-Q2 | — | $3.1M | $35M+ $65M short-term inv. | $8.5M-$5.1M operating cash flow | report ↗ |
| 2022-Q1 | — | $5.3M | $26M+ $62M short-term inv. | $11M-$11M operating cash flow | report ↗ |
| 2021-Q3 | — | $4.1M | $41M+ $53M short-term inv. | $11M-$6.2M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $43M | $50M+ $106M short-term inv. | $14M-$56M operating cash flow | report ↗ |
Protara did not disclose revenue for 2025. Full-year R&D expense was $42.6M, up 34.5% YoY from $31.7M, and the company reported a net loss of $57.4M, or $1.34 per share. Cash, cash equivalents and marketable debt securities totaled $197.9M as of December 31, 2025, including proceeds from an $86.3M public offering, and the company expects this to fund planned operations into 2028.
Clinically, Protara reported ADVANCED-2 interim data in non-muscle invasive bladder cancer showing a 68% complete response rate at six months in BCG-unresponsive patients, and it received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations. The company expects to complete enrollment of the BCG-unresponsive registrational cohort and initiate the ADVANCED-3 registrational trial in 2H 2026, with a regulatory update for lymphatic malformations expected in 1H 2026 and THRIVE-3 interim results expected in 2H 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $32M | $164M+ $7.5M short-term inv. | $11M-$36M operating cash flow | report ↗ |
| 2023-FY | — | $25M | $40M+ $26M short-term inv. | $10M-$38M operating cash flow | report ↗ |
| 2022-FY | — | $17M | $25M+ $60M short-term inv. | $16M-$26M operating cash flow | report ↗ |
| 2021-FY | — | $21M | $36M+ $56M short-term inv. | $12M-$35M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 3 sales ($1.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-30 | Shefferman Jesse · director, CEO and President | Gift | 14,000 | — | — | Form 4 |
| 2026-06-30 | Shefferman Jesse · director, CEO and President | Gift | 7,000 | — | — | Form 4 |
| 2026-06-30 | Shefferman Jesse · director, CEO and President | Gift | 4,000 | — | — | Form 4 |
| 2026-06-30 | Shefferman Jesse · director, CEO and President | Gift | 5,000 | — | — | Form 4 |
| 2026-06-29 | Shefferman Jesse · director, CEO and President | Option exercise | 215,687 | $1.91 | $412K | Form 4 |
| 2026-06-29 | Shefferman Jesse · director, CEO and President | Open-market sale | 215,687 | $4.09 | $882K | Form 4 |
| 2026-06-29 | Shefferman Jesse · director, CEO and President | Option exercise (derivative) | 215,687 | — | — | Form 4 |
| 2026-06-15 | BESHAR LUKE M · director | Award / grant (derivative) | 31,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 113 reporting institutions held 45.6M shares ($237.1M, 81.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 5,207,011 | $27.2M |
| 2 | BlackRock, Inc. | 3,394,968 | $17.7M |
| 3 | Velan Capital Investment Management LP | 2,834,652 | $14.8M |
| 4 | MILLENNIUM MANAGEMENT LLC | 2,831,208 | $14.8M |
| 5 | Blackstone Inc. | 2,265,514 | $11.8M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2,119,018 | $11.0M |
| 7 | Sio Capital Management, LLC | 1,969,839 | $10.3M |
| 8 | ACORN CAPITAL ADVISORS, LLC | 1,752,115 | $9.1M |
| 9 | Integral Health Asset Management, LLC | 1,750,000 | $9.1M |
| 10 | AIGH Capital Management LLC | 1,622,733 | $8.5M |
| 11 | UBS Group AG | 1,402,413 | $7.3M |
| 12 | 5AM Venture Management, LLC | 1,369,782 | $7.1M |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1,177,200 | $6.1M |
| 14 | Point72 Asset Management, L.P. | 1,152,714 | $6.0M |
| 15 | CITADEL ADVISORS LLC | 1,068,558 | $5.6M |